Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Protega’s ROXYBOND™ Gets FDA Approval As Abuse-Deterrent Pain Management Option
Details : Roxybond (oxycodone HCl) is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Product Name : Roxybond
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2020
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Proteus
Deal Size : Inapplicable
Deal Type : Inapplicable
S1916 Digital Medicine Program for Pain Control in Cancer Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2019
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Proteus
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Ambit Biosciences | Kern Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2019
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Ambit Biosciences | Kern Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase IV
Sponsor : Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Pain Control Following Sinus Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2018
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase IV
Sponsor : Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2018
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : ZonMw | Envida, Maastricht, The Netherlands
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2018
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : ZonMw | Envida, Maastricht, The Netherlands
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Collegium Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills
Details : Undisclosed
Product Name : Xtampza ER
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2018
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Collegium Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OTR Tablet 10 mg Fasted-state Bioequivalence Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2018
Lead Product(s) : Oxycodone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable